AB 319: Narcotic treatment: medication-assisted treatment: Drug Medi-Cal.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-03-25
|
Date
|
Status
|
|---|---|
| Feb 3, 2020 | From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. |
| Jan 31, 2020 | Died pursuant to Art. IV, Sec. 10(c) of the Constitution. |
| May 16, 2019 | In committee: Held under submission. |
| Apr 24, 2019 | In committee: Set, second hearing. Referred to APPR. suspense file. |
| Apr 10, 2019 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Mar 26, 2019 | Re-referred to Com. on APPR. |
| Mar 25, 2019 | Read second time and amended. |
| Mar 21, 2019 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (March 19). |
| Feb 11, 2019 | Referred to Com. on HEALTH. |
| Jan 31, 2019 | From printer. May be heard in committee March 2. |
| Jan 30, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Mar 19, 2019 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Date of Hearing: April 24, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 319
Author:(Blanca Rubio and Waldron) – As Amended Ver:March 25, 2019
Policy Committee: | Health | Vote: | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: Yes
SUMMARY:
This bill requires the Department of Health Care Services (DHCS) to establish reimbursement rates and billing codes for any medications authorized for use in medication-assisted treatment for substance use disorders (SUDs), as well as related services such as evaluation, dispensing and counseling that are provided by any narcotic treatment program electing to provide noncontrolled medications for SUD treatment.
FISCAL EFFECT:
- One-time administrative costs to DHCS in the range of $50,000 to $100,000 (GF/federal) to submit and gain federal approval for a state plan amendment to cover additional drugs and services statewide.
- Unknown, significant cost pressure, potentially in the millions (GF/federal), to reimburse counties pursuant to Proposition 30 for any additional cost of providing Medi-Cal coverage for noncontrolled drugs commonly provided by NTPs and associated services used in medication-assisted treatment. (See below for a description of how Proposition 30 protections apply to this bill.)
- Unknown future cost pressure to cover unknown future drugs that may be developed, along with associated services. Because the reference in this bill is to any FDA-approved medication used for medication-assisted treatment for SUD, the potential cost to cover future drugs is unknown but could be significant.
COMMENTS:
- Purpose. According to the author, this bill is needed to reimburse narcotic treatment program providers for medication-assisted treatment (MAT) for SUD, when providing non-controlled medications.
- Background. Narcotic treatment programs (NTPs) are specialty substance use disorder providers that historically were primarily “methadone clinics,” which deliver daily doses of methadone maintenance treatment to persons addicted to opioids. Although methadone is still a large service category, the medications used in MAT for substance use have been dramatically broadened. Since last year, NTPs have been authorized to provide an array of medications and related services for substance use, including for alcohol abuse. However, not all NTPs are able to be reimbursed through Medi-Cal for this expanded list of medications and related services.
DHCS licenses public and private NTPs and monitors them for compliance with applicable state law and regulation. Federal accreditation and certification is also required for NTPs (these programs are called opioid treatment programs (OTPs) in federal regulations).
Methadone and buprenorphine are considered controlled substances, while other drugs are non-controlled (such as naltrexone, which is used to treat alcohol dependence as well as to prevent relapse of opioid use). As the name implies, MAT is not exclusively pharmacological, but also includes related treatment services, such as counseling.
SUD treatment in Med-Cal was realigned along with the state’s major 2011 criminal justice realignment. A wholesale transformation is underway in county-based Medi-Cal SUD treatment, which is transitioning from a disjointed smattering of providers with minimal services to an organized delivery system with a common level-of-care assessment and a robust package of services. This effort is called the Drug Medi-Cal Organized Delivery System (DMC-ODS), and is made available through a federal waiver and at county option. Most counties have opted in to provide this more-robust level of services available through the DMC-ODS. In these counties, NTPs must provide a certain expanded list of medications for MAT. Other medications can be covered at county option. Outside of DMC-ODS counties, coverage for MAT is limited.
This bill would essentially allow NTPs to provide, and would require the Medi-Cal program to cover statewide, any noncontrolled medications approved by the U.S Food and Drug Administration (FDA) to treat SUD, as well as associated services.
- Proposition 30. Proposition 30 of 2012 provides protection for realigned revenue sources and programs. It specifies that legislation enacted after September 30, 2012, "that has an overall effect of increasing the costs already borne by a local agency for programs or levels of service mandated by the 2011 Realignment Legislation” apply to local agencies “only to the extent that the State provides annual funding for the cost increase." Thus, as the bill mandates higher level of service in a realigned program that is protected by this Proposition 30 structure, the bill would only apply to counties to the extent additional state funding was provided.
- Staff Comments. It is unclear why the bill requires DHCS to “establish reimbursement rates” and whether the lack of reimbursement rates is the barrier to reimbursement, as opposed to lack of coverage. Since it appears these services are not currently covered, at least when provided by an NTP, the author may wish to consider requiring Medi-Cal coverage for the drugs and NTP services this bill wishes to cover; reimbursement rates will naturally follow. This would provide greater legal and programmatic clarity.
In addition, this bill raises fiscal and policy issues related to the realignment and local control, delivery and funding of drug treatment services. For instance, this bill would substitute state funding for drugs that are currently covered at county expense. Potential benefits of statewide mandated coverage must be weighed against the state costs and state interest in implementing the DMC-ODS, which envisions local decision-making about covering additional drugs.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 10, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 319
Author:(Blanca Rubio and Waldron) – As Amended Ver:March 25, 2019
Policy Committee: | Health | Vote: | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: Yes
SUMMARY:
This bill requires the Department of Health Care Services (DHCS) to establish reimbursement rates and billing codes for any medications authorized for use in medication-assisted treatment for substance use disorders (SUDs), as well as related services such as evaluation, dispensing and counseling that are provided by any narcotic treatment program electing to provide noncontrolled medications for SUD treatment.
FISCAL EFFECT:
- One-time administrative costs to DHCS in the range of $50,000 to $100,000 (GF/federal) to submit and gain federal approval for a state plan amendment to cover additional drugs and services statewide.
- Unknown, significant cost pressure, potentially in the millions (GF/federal), to reimburse counties pursuant to Proposition 30 for any additional cost of providing Medi-Cal coverage for noncontrolled drugs commonly provided by NTPs and associated services used in medication-assisted treatment. (See below for a description of how Proposition 30 protections apply to this bill.)
- Unknown future cost pressure to cover unknown future drugs that may be developed, along with associated services. Because the reference in this bill is to any FDA-approved medication used for medication-assisted treatment for SUD, the potential cost to cover future drugs is unknown but could be significant.
COMMENTS:
- Purpose. According to the author, this bill is needed to reimburse narcotic treatment program providers for medication-assisted treatment (MAT) for SUD, when providing non-controlled medications.
- Background. Narcotic treatment programs (NTPs) are specialty substance use disorder providers that historically were primarily “methadone clinics,” which deliver daily doses of methadone maintenance treatment to persons addicted to opioids. Although methadone is still a large service category, the medications used in MAT for substance use have been dramatically broadened. Since last year, NTPs have been authorized to provide an array of medications and related services for substance use, including for alcohol abuse. However, not all NTPs are able to be reimbursed through Medi-Cal for this expanded list of medications and related services.
DHCS licenses public and private NTPs and monitors them for compliance with applicable state law and regulation. Federal accreditation and certification is also required for NTPs (these programs are called opioid treatment programs (OTPs) in federal regulations).
Methadone and buprenorphine are considered controlled substances, while other drugs are non-controlled (such as naltrexone, which is used to treat alcohol dependence as well as to prevent relapse of opioid use). As the name implies, MAT is not exclusively pharmacological, but also includes related treatment services, such as counseling.
SUD treatment in Med-Cal was realigned along with the state’s major 2011 criminal justice realignment. A wholesale transformation is underway in county-based Medi-Cal SUD treatment, which is transitioning from a disjointed smattering of providers with minimal services to an organized delivery system with a common level-of-care assessment and a robust package of services. This effort is called the Drug Medi-Cal Organized Delivery System (DMC-ODS), and is made available through a federal waiver and at county option. Most counties have opted in to provide this more-robust level of services available through the DMC-ODS. In these counties, NTPs must provide a certain expanded list of medications for MAT. Other medications can be covered at county option. Outside of DMC-ODS counties, coverage for MAT is limited.
This bill would essentially allow NTPs to provide, and would require the Medi-Cal program to cover statewide, any noncontrolled medications approved by the U.S Food and Drug Administration (FDA) to treat SUD, as well as associated services.
- Proposition 30. Proposition 30 of 2012 provides protection for realigned revenue sources and programs. It specifies that legislation enacted after September 30, 2012, "that has an overall effect of increasing the costs already borne by a local agency for programs or levels of service mandated by the 2011 Realignment Legislation” apply to local agencies “only to the extent that the State provides annual funding for the cost increase." Thus, as the bill mandates higher level of service in a realigned program that is protected by this Proposition 30 structure, the bill would only apply to counties to the extent additional state funding was provided.
- Staff Comments. It is unclear why the bill requires DHCS to “establish reimbursement rates” and whether the lack of reimbursement rates is the barrier to reimbursement, as opposed to lack of coverage. Since it appears these services are not currently covered, at least when provided by an NTP, the author may wish to consider requiring Medi-Cal coverage for the drugs and NTP services this bill wishes to cover; reimbursement rates will naturally follow. This would provide greater legal and programmatic clarity.
In addition, this bill raises fiscal and policy issues related to the realignment and local control, delivery and funding of drug treatment services. For instance, this bill would substitute state funding for drugs that are currently covered at county expense. Potential benefits of statewide mandated coverage must be weighed against the state costs and state interest in implementing the DMC-ODS, which envisions local decision-making about covering additional drugs.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: March 19, 2019
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 319 (
Author:Blanca Rubio) – As Introduced Ver:January 30, 2019
SUBJECT: Narcotic treatment: medication-assisted treatment
SUMMARY: Requires the Department of Health Care Services (DHCS) to establish reimbursement rates and rate billing codes for medication assisted treatment (MAT) services provided by licensed narcotic treatment programs (NTPs) electing to provide noncontrolled medications approved by the federal Food and Drug Administration (FDA) for patients with a substance use disorder (SUD). Specifically, this bill:
- Requires DHCS to establish reimbursement rates and rate billing codes for MAT services provided by licensed NTPs electing to provide noncontrolled medications approved by the FDA for patients with a SUD.
- Permits, under existing law authority, DHCS to implement, interpret, or make specific this bill by means of plan or provider bulletins, or similar instructions. Requires DHCS, under existing law, to adopt regulations by no later than January 1, 2021.
EXISTING LAW:
- Authorizes licensed NTPs to use the following medications for use in narcotic replacement therapy (NRT) and MAT:
- Methadone;
- Levo-alpha-acetylmethadol as specified;
- Buprenorphine products or combination of products approved by the FDA for maintenance or detoxification of opioid dependence; and,
- Any other medication approved by the FDA for the purpose of NRT or MAT of SUDs.
- Requires DHCS to be responsible for licensing NTPs to use NRT and MAT in the treatment of addicted persons whose addiction was acquired or supported by the use of alcohol or a narcotic drug or drugs, not in compliance with a physician’s legal prescription.
- Prohibits a NTP from being authorized to use narcotic replacement therapy and MAT without first obtaining a license as a NTP.
- Permits DHCS to license NTPs on an inpatient or outpatient basis, or both, and permits DHCS to also grant a state narcotic treatment license.
- Requires DHCS to establish a NRT dosing fee for methadone, and requires NTPs to be reimbursed for the dosing fee and the ingredient costs of methadone dispensed to Medi-Cal beneficiaries.
- Requires reimbursement to NTPs for program services to be limited to those services specified in state law and state and federal regulations governing the licensing and administration of NTPs, and requires these services to include, but not be limited to, all of the following:
- Admission, physical evaluation, and diagnosis;
- Drug screening;
- Pregnancy tests;
- NRT dosing; and,
- Intake assessment, treatment planning, and counseling services.
- Requires, under the State Constitution as enacted by Proposition 30 of 2012, legislation enacted after September 30, 2012, that has an overall effect of increasing the costs already borne by a local agency for programs or levels of service mandated by the 2011 Realignment Legislation to apply to local agencies only to the extent that the State provides annual funding for the cost increase. Prohibits local agencies from being obligated to provide programs or levels of service required by legislation above the level for which funding has been provided.
FISCAL EFFECT: This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, the choice of available treatment options for addiction involving opioid use should be a shared decision between a clinician and patient. This bill will provide patients and clinicians with the option of picking the most suitable treatment plan tailored to the individual by requiring DHCS to provide the necessary wrap-around services for any medication approved for addiction treatment by the FDA.
- BACKGROUND. California’s NTPs provide opioid MAT (such as methadone) to those persons addicted to opiates. NTPs also provide detoxification and/or maintenance treatment services which include medical evaluations and rehabilitative services. There are nearly 170 NTPs statewide.
AB 395 (Bocanegra), Chapter 223, Statutes of 2017, expanded the types of medications authorized for use by licensed NTPs and broadened the purpose for which the expanded medications could be used. Prior to AB 395, NTPs were only allowed to use controlled substances for the purpose of NRT. The NRT controlled substances include full agonist medication (methadone) and partial agonist medication (buprenorphine products). AB 395 allowed NTPs to use any FDA-approved medications (instead of just controlled substances) for MAT (instead of just NRT). The expanded MAT medications include Naltrexone (used for the treatment of alcohol dependence and the prevention of relapse to opioid dependence, taken by mouth or by injection), Disulfiram (an aid in the management of selected chronic alcohol patients), Acamprosate (used for the maintenance of abstinence from alcohol in patients with alcohol dependence), and Naloxone (used to reverse an opioid overdoes).
In a Mental Health and SUDs Information Notice (18-004) issued by DHCS on implementing AB 395, DHCS indicated NTPs electing to provide expanded MAT services under AB 395 are required to submit an amended protocol in writing to DHCS in accordance with an existing regulation prior to providing expanded MAT services. However, DHCS noted that AB 395 did not add funding for expanded MAT services.
- DRUG MEDI-CAL. The scope of Drug Medi-Cal (DMC) services varies by county depending upon whether the county opted-in to the state’s Drug Medi-Cal Organized Delivery System (DMC-ODS). In August 2015, DHCS received approval from the Centers for Medicare and Medicaid Services to implement the DMC-ODS waiver. The DMC-ODS is a pilot project authorized originally under California’s Section 1115 Bridge to Reform Demonstration Waiver and continued in the Medi-Cal 2020 Waiver. The purpose of the pilot program is to test a new paradigm for organized delivery of health care services for Medicaid eligible individuals with a SUD.
DMC-ODS waiver services include the existing treatment modalities, and additional new and expanded county optional services. Counties that opt-in to participate in the DMC-ODS waiver are required to provide a continuum of care to all eligible beneficiaries modeled after the American Society of Addiction Medicine criteria. For medications, NTPs in DMC-ODS counties have to provide methadone, buprenorphine, Disalfiram, and Naloxone. Counties contracting to participate in DMC-ODS can choose to offer additional MAT beyond the required NTP services. The rates for optional MAT services (such as long-acting injectable Naltrexone) are developed by each county and are subject to DHCS approval. A total of 39 opt-in counties are estimated to provide DMC-ODS waiver services in fiscal year 2018- 19.
This bill seeks to allow NTPs to be able to bill Medi-Cal for the newly expanded noncontrolled FDA-approved medications by requiring DHCS to establish reimbursement rates and rate billing codes for MAT services (such as counseling, drug testing and urinalysis) provided by NTPs electing to provide these medications. The practical effect of this bill would be to provide DMC coverage statewide for those non-controlled drugs authorized by AB 395 in NTPs, with the related counseling and drug testing services. This contrasts with existing coverage for NTPs, where the optional drugs are only covered if the DMC-ODS county opts in to covering the optional medications, and DHCS approves. - COVERAGE OUTSIDE NTPs. MAT services are available outside of DMC-ODS and under certain circumstances. SUD treatment providers can offer certain MAT services by enrolling as Medi-Cal fee-for-service providers. For example, Naltrexone long-acting injection (Vivitrol) is a covered benefit of the Medi-Cal program and is available to all Medi-Cal beneficiaries who demonstrate a medical necessity for the use of the drug. It may be billed as either a medical claim or a pharmacy claim.
Selected alcohol and heroin detoxification and dependency treatment drugs, including Naltrexone for extended-release injectable suspension, are “carved out” of coverage through Medi-Cal managed care plans. These drugs must instead be billed as a fee-for-service claim. DHCS indicates that Naltrexone for long-acting injection always requires a Treatment Authorization Request (TAR) when billed as either a medical or pharmacy benefit. TARs require approval from DHCS staff and are a form of utilization control. Medi-Cal also covers the following medications for the treatment of alcohol and opioid dependence and/or prevention of relapse: Acamprosate, Buprenorphine, Buprenorphine/Naloxone, Disulfiram, and oral Naltrexone (a TAR is required for all but Disulfiram and oral Naltrexone). - SUPPORT. Alkermes (a biopharmaceutical company and manufacturer of Vivitrol) writes in support of this bill to direct DHCS to set a code for non-controlled therapies in the NTP setting. Alkermes writes that AB 395 was signed into law but DHCS has now identified additional steps needed to enable practical implementation of the legislative changes to allow non-narcotic treatment for opioid use disorder within the NTP treatment system. Alkermes writes that, while it does not believe there is a need for additional funding, what is needed is an NTP rate to be established that would allow for reimbursement of services used in conjunction with the non-narcotic medications. Alkeremes concludes that not having a way for NTPs to be reimbursed for the services associated with using one of the three FDA-approved medications is directly at odds with the stated objective of DHCS to expand capacity in the NTP setting for all FDA-approved medications.
- RECOMMENDED AMENDMENT. By requiring DHCS to establish reimbursement rates and rate billing codes for MAT services provided by NTPs electing to provide noncontrolled medications for patients with a SUD, this bill is intended to allow NTPs to bill for services they provide when dispensing methadone and other medications (such as counseling, drug screening, assessment, treatment planning). However this bill is placed in the Health and Safety Code when Medi-Cal provisions are typically located in the Welfare and Institutions Code (W&I Code), and it uses the phrase “medication-assisted treatment services” to reference the services NTPs can currently bill for when billing for methadone. The Committee may wish to move the language in this bill the W&I Code, and to cross reference the existing law provisions providing reimbursement for the related services NTPs provide (instead of using the phrase “MAT services”), as follows:
14021.51.5 is added to the Welfare and Institutions Code to read:
- The department shall establish reimbursement rates and rate billing codes for medications authorized for use pursuant to subdivision (d) of Section 11839.2 of the Health and Safety Code that include the services in subdivision (f) in Section 14021.51 that are provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a SUD.
- Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
REGISTERED SUPPORT / OPPOSITION:
Support
Alkermes
Mental Health America of California
Opposition
None received
Analysis Prepared by: Scott Bain / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):